Нow to increase the effectiveness of eradication therapy of Helicobacter pylori infection?
https://doi.org/10.30629/0023-2149-2022-100-1-47-50
Abstract
The article discusses various measures that may be taken to increase the effectiveness of eradication of Helicobacter pylori, taking into account the growing resistance of this infection to antibiotics. These include: refusal to use standard triple therapy in an isolated form, 14-day duration of the course of eradication, inclusion of bismuth preparations in combination with various antibiotics in the schemes of eradication therapy, preference for the appointment of proton pump inhibitors such as rabeprazole and esomeprazole (in double dose, if necessary), additional inclusion in the schemes of eradication of probiotics and rebamipide, increased adherence of patients to treatment.
About the Authors
A. A. Sheptulin
I. M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University
Russian Federation
Russian Federation
Sheptulin Arkadii A.
119991, Moscow
Yu. S. Rabotyagova
Medical Academy named after S. I. Georgievsky of V. I. Vernadsky Crimean Federal University
Russian Federation
Russian Federation
Rabotyagova Yulia S.
295051, Simferopol
References
1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus report. Gut. 2017;66(1):6–30. Published Online First on October 5, 2016. DOI: 10.1136/gutjnl-2016-312288
2. Ivashkin V.T., Mayev I.V., Lapina T.L. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross. Z. Gastroenterol. Gepatol. Koloproktol. 2018;28(1):55–70. (In Russian). DOI: 10.22416/1382-4376-2018-28-1-55-70
3. Ivashkin V.T., Mayev I.V., Kaprin A.D et al. Early detection of oncological diseases of the digestive system (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for primary care physicians). Rosssiskii zhurnal gastroenteroljgii, gepatoljgii, koloproktologii. 2019;29(5):53–74. (In Russian). DOI:10.22416/1382-4376-2019-29-5-53-74
4. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. DOI: 10.1136/gutjnl-2015-309252
5. Jung H.-K., Kang S.J., Lee Y.C. et al. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021;15(2):168–195. DOI: 10.5009/gn120288
6. Fallone C.A., Chiba N., Veldhuyzen van Zanten S. et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):59–69. DOI: 10.1053.2016.04.006
7. Chey W.D., Leontiadis G.I., Howden C.W., Moss S.F. ACG clinical guidelines: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 2017;112(2):212–239. DOI: 10.1038/ajg.2016.563
8. Fallone C.A., Moss S.F., Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44–53. DOI: 10.1053/j.gastro.2019.04.011
9. Kim S.Y., Chung J.-W. Best Helicobacter pylori eradication strategy in the era of antibiotic resistance. Antibiotics (Basel). 2020;9(8):436. DOI: 10.3390/antibiotics908436
10. Boltin D., Beniashvili Z., Lahat A. et al. European Registry on Helicobacter pylori management (Hp-EuReg): first-line therapy in Israel. Isr. Med. Assoc. J. 2021;23(1);38-42.
11. Liu C., Wang Y., Shi J. et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap. Adv. Gastroenterol. 2021;14:1756284821989177. DOI: 10.1177/1756284821989177
12. Gispert J.P., Alcedo J., Amador J. et al. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Rev. Esp. Enferm. Dig. 2021;113(10). DOI: 10.17235/reed.2021.8358/2021
13. Graham D.Y., Lee Y.-C., Wu M.-S. Rational Helicobacter pylori therapy: evidence based medicine rather than medicine based evidence (revision 2). Clin. Gastroenterol. Hepatol. 2014;12(2):177– 186. DOI: 10.1016/j.cgh.2013.05.028
14. Graham D., Dore M.P., Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert. Rev. Anti. Infect. Ther. 2018;16(9):679– 687. DOI: 10.1080/14787210.2018.1511427
15. Ivashkin V.T., Mayev I.V., Lapina T.L. et al. Treatment of Helicobac ter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Ad visory council resolution, May 19, 2017). Rossiskii zhurnal gastro enteroljgii, gepatoljgii, koloproktologii. 2017;27(4):4–21. (In Russian). DOI: 10.22416/13824376201727442.1
16. Suzuki S., Esaki M., Kusano C. et al. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J. Gastroenterol. 2019;25(16):1907–1912. DOI: 10.3748/wjg.v25.i16.1907
17. Suzuki S., Kusano C., Horii T. et al. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022:62–68. DOI: 10.1159/000519413
18. Gao C.-P., Zhang D., Zhang T. et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692. DOI: 0.1111/hel.12692
19. Ji J., Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int. J. Mol. Sci. 2020Feb8;21(3):1136. DOI: 10.3390/ijms21031136
20. Nishizawa T., Nishizawa Y., Yahagi N. et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systemic review and meta-analysis. J. Gastroenterol. Hepatol. 2014;29(4):20–24. DOI: 10.1111/jgh.12769
Review
For citations:
Sheptulin A.A., Rabotyagova Yu.S. Нow to increase the effectiveness of eradication therapy of Helicobacter pylori infection? Clinical Medicine (Russian Journal). 2022;100(1):47-50. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-1-47-50
Views:
529
Email this article 